Nephronomics, a Costa Mesa, California-based AI and precision medicine company focused on cardio-kidney-metabolic disease, has received a strategic investment from CerraCap Ventures, a Southern California early-stage venture capital firm. Financial terms of the investment were not disclosed.
Nephronomics is a joint venture between Mechanica Partners and Fresenius Medical Care, and is building what it describes as one of the world’s most comprehensive clinical and genomic datasets focused on the intersection of cardiovascular, kidney, and metabolic disorders, a disease framework known as cardio-kidney-metabolic, or CKM, disease. The company’s core asset is exclusive access to the largest renal dataset globally, spanning more than 42,000 consented patients across a significant portion of U.S. dialysis clinics. The Nephronomics Atlas contains matching whole genome and longitudinal clinical data, including comprehensive laboratory data, diagnosis histories, treatments, and raw radiology images for patients with advanced chronic kidney disease and end-stage kidney disease.
The company is translating this proprietary dataset into actionable biological insight using advanced machine learning, including protein modeling, variant-effect prediction, and generative design, to identify new disease subtypes, uncover causal mechanisms, and develop novel therapeutic targets. The approach is designed to enable a shift from correlation to causation in drug discovery, accelerating the development of precision therapies that directly address disease-driving molecular pathways. Nephronomics intends to build an internal pipeline of therapeutic programs while also partnering with pharmaceutical companies to accelerate drug development.
The opportunity is significant. Chronic kidney disease affects 14% of the U.S. population and 850 million people globally, yet despite more than $141 billion in annual U.S. spending, the disease remains under-researched relative to its scale, creating a clear opening for precision medicine approaches. For CerraCap, the investment aligns with the firm’s focus on backing AI-native infrastructure that enables systemic transformation across industries. CerraCap’s platform includes a Sales & Scale business model designed to drive revenue from large enterprises into its portfolio companies.
KEY QUOTES:
“This is not simply about applying AI to existing workflows. It’s about enabling an entirely new intelligence layer for healthcare and life sciences. Nephronomics will not only accelerate innovation in kidney disease but also demonstrate how the future of medicine will be built: on intelligent systems powered by data, driven by insight, and scaled through strategic ecosystems.”
Vikas Datt, CerraCap Ventures
“CerraCap shares our conviction that the ESKD population represents one of the most genetically informative cohorts in CKM disease — enriched signals of both protective and harmful variants that are uniquely powerful for therapeutic target discovery. Their experience backing applied AI companies and their investment here supports our work translating those signals into precision therapies across the cardio-kidney-metabolic spectrum.”
Deniz Kural, Chief Science Officer and Founder, Nephronomics
